Safety of the treatment with retinoids;Bezpieczeństwo stosowania retinoidów

Postepy Dermatologii i Alergologii

Volumn 23, Issue 4, 2006, Pages 161-174

  Zaba, Ryszard ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Biological functions; Retinoids; Side effects

Indexed keywords

ADAPALENE; ALITRETINOIN; BEXAROTENE; CAROTENE; ETRETIN; ETRETINATE; ISOTRETINOIN; MOTRETINIDE; RETINAL; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL; RETINOL ESTER; TAZAROTENE;

ACNE VULGARIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LOCAL THERAPY; MORPHOGENESIS; REGULATORY MECHANISM; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 33749236042     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 1925; 42: 753-78.
2. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. Springer-Verlag, Berlin-Heidelberg-New York, 2000.
3. Kuenzil S, Saurat JH. Retinoids In: Dermatology. Bolognia JL, Jorizzo JL, Raponi RP (eds). Mosby, 2003: 1991-2006.
4. Wegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998; 39: S25-33.
5. Ethan-Quan HN, Wolverton S. Systemic retinoids. In: Wolverton SE (ed.). Comprehensive Dermatology Drug Therapy. Philadelphia: WB Saunders, 2001: 269-310.
6. Bergler-Czop B, Brzezińska-Wcisło L. Wyniki leczenia tradziku skupionego preparatem izotretinoiny - obserwacja w materiale Kliniki Dermatologii Ślaskiej Akademii Medycznej. Derm Klin 2005; 2: 73-7.
7. Stratigos AJ, Katsambas AD. The role of topical retinoids in the treatment of photoaging. Drugs 2005; 65: 1061-72.
8. Dong D, Ruuska SE, Levinthal DJ, et al. Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid. J Biol Chem 1999; 274: 23695-8.
9. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987; 16: 267-91.
10. Thacher SM, Standeven AM, Athaniker J, et al. Receptor specificity of retinoid-induced epidermal hyperplasia: effect of RXR-selective agonists and correlation with topical irritation. J Pharmacol Exp Ther 1997; 282: 528-34.
11. Ceiger JM, Saurat JH. Acitretin and etretinate. Dermatol Clin 1993; 11: 117-29.
12. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988; 176: 182-90.
13. Wolska H, Langner A. Łuszczyca. Wydawnictwo Czelej, Lublin 2006.
14. Prystowsky J. Topical retinoids. In: Se W (ed). Comprehensive Dermatologie Drug Therapy. Philadelphia: Saunders, 2001.
15. Caron D, Sorba V, Kerrouche N, et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997; 36: 110-12.
16. Błaszczyk-Kostanecka M, Chodynicka B, Gliński W i wsp. Tradzik pospolity: patogeneza i zasady leczenia. Przegl Dermatol 1998; 85: 3-19.
17. Kłujszo E, Langner A. Ocena różnych metod leczenia tradziku łagodnego i średnio nasilonego. Przegl Dermatol 2006; 93, 1: 47-56.
18. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997; 36: S126-34.
19. Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18-24.
20. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma [letter]. N Engl J Med 1999; 341: 1767-9.
21. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial with bexarotene gel for skin-directed treatment of patients with cutaneous T celi lymphoma. Arch Dermatol 2002; 138: 325-32.
22. Cuzzell JZ. FDA approves mandatory risk management program for isotretinoin. Dermatol Nurs 2005; 17: 383.
23. Loureiro KD, Kao KK, Jones KL, i wsp. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136: 117-21.
24. Williams RE, Doherty VR, Perkins W, et al. Staphylococcus aureus and intra-nasal mupirocin in patients receiving isotretinoin for acne. Br J Dermatol 1992; 126: 362-6.
25. Zaba R, Biegalska J, Kaszewski S, i wsp. Ocena skuteczności i tolerancji izotretynoiny (Roaccutane) w leczeniu tradziku pospolitego. Nowiny Lekarskie 2000; 69, 11: 938-44.
26. Safran AB, Haliaoua B, Roth A, et al. Ocular side-effects of orał treatment with retinoids. In: Saurat JH (ed). Retinoids: 10 years on. Basel: Karger, 1991: 315-26.
27. David M, Hodak E, Lowe N. Adverse effects of retinoids. Med Toxicol 1988; 3: 273-88.
28. Carey BM, Parkin CJ, Cuniiffe WJ, et al. Skeletal toxicity with isotretinoin therapy: a clinico-radiological evaluation. Br J Dermatol 1988; 119: 609-14.
29. Kilcoyne RF. Effects of retinoids in bone. J Am Acad Dermatol 1988; 19: 212-16.
30. DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995; 131: 1263-7.
31. Lister RK, Lecky BR, Lewis-Jones MS, et al. Acitretin-induced myopathy. Br J Dermatol 1996; 134: 989-90.
32. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotick symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231-6.
33. Fex GA, Aronsson A, Andersson A. Safety of Accutane with possible depression. Postgrad Med 1998; 34: 38.
34. Cuniiffe WJ, van de Kerkhof PCM, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351-7.
35. David M, Hodak E, Lowe N. Adverse effects of retinoids. Med Toxicol 1988; 3: 273-88.
36. Vahlquist C, Olsson A, Lindholm A, et al. Effects of gemfibrozil (Lopid®) on hyperlipidemia in acitretin-treated patients. Acta Derm Venereol 1995; 75: 377-80.
37. Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41: 584-8.
38. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase I-III trial results. J Clin Oncol 2001; 19: 2456-71.
39. Cribier B, Welsch M, Heid E. Renal impairment probably induced by etretinate. Dermatology 1992; 185: 266-8.
40. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
41. Berbis P, Bun H, Geiger JM, et al. Acitretin (RO10-1670) and oral contraceptives: interaction study. Arch Dermatol Res 1988; 280: 388-9.
42. Zaba R, Grzybowski G. Leczenie tradziku różowatego izotretinoina. Dermatologia Estetyczna 1999; 1: 106-111.
43. Kang S, Li XY, Duell EA, et al. The retinoid X receptor agonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. J Invest Dermatol 1997; 108: 513-18.
44. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12.